Abionyx Pharma SA Cash Flow Conversion Efficiency
Abionyx Pharma SA cash flow conversion efficiency. Based on the latest financial reports, Abionyx Pharma SA (ABNX) has a cash flow conversion efficiency ratio of -0.314x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.70 Million ≈ $-1.99 Million USD) by net assets (€5.41 Million ≈ $6.33 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Abionyx Pharma SA (2013–2024)
Cash flow conversion efficiency of Abionyx Pharma SA from 2013 to 2024. This chart illustrates how Abionyx Pharma SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Abionyx Pharma SA (ABNX) share price today for real-time trading data and today's change.
Abionyx Pharma SA Cash Flow Conversion Ratio Explained
Abionyx Pharma SA cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Abionyx Pharma SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Abionyx Pharma SA ranked by their cash flow conversion efficiency. Also see Abionyx Pharma SA market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ekadharma International Tbk
JK:EKAD
|
0.026x |
|
Sreeleathers Limited
NSE:SREEL
|
0.037x |
|
Northview Acquisition Corp
NASDAQ:NVAC
|
0.029x |
|
HLB Global Co Ltd
KO:003580
|
-0.045x |
|
Chungdamglobal Co. Ltd.
KQ:362320
|
-0.095x |
|
EML Payments Ltd
AU:EML
|
-0.225x |
|
Ariadne Australia Ltd
AU:ARA
|
0.038x |
|
Quest For Growth - Pricaf
BR:QFG
|
-0.014x |
Annual Cash Flow Conversion Efficiency for Abionyx Pharma SA (2013–2024)
The table below shows the annual cash flow conversion efficiency of Abionyx Pharma SA from 2013 to 2024. Review ABNX free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €7.42 Million ≈ $8.68 Million |
€-3.60 Million ≈ $-4.21 Million |
-0.485x | -3.88% |
| 2023-12-31 | €7.92 Million ≈ $9.26 Million |
€-3.70 Million ≈ $-4.32 Million |
-0.467x | +0.37% |
| 2022-12-31 | €7.17 Million ≈ $8.38 Million |
€-3.36 Million ≈ $-3.93 Million |
-0.469x | +25.24% |
| 2021-12-31 | €10.68 Million ≈ $12.48 Million |
€-6.69 Million ≈ $-7.82 Million |
-0.627x | -593.63% |
| 2020-12-31 | €6.63 Million ≈ $7.75 Million |
€-599.00K ≈ $-700.29K |
-0.090x | +84.75% |
| 2019-12-31 | €6.67 Million ≈ $7.79 Million |
€-3.95 Million ≈ $-4.62 Million |
-0.593x | +62.11% |
| 2018-12-31 | €3.84 Million ≈ $4.49 Million |
€-6.00 Million ≈ $-7.02 Million |
-1.564x | -52.89% |
| 2017-12-31 | €8.89 Million ≈ $10.39 Million |
€-9.09 Million ≈ $-10.63 Million |
-1.023x | +22.15% |
| 2016-12-31 | €14.61 Million ≈ $17.08 Million |
€-19.20 Million ≈ $-22.44 Million |
-1.314x | -218.16% |
| 2015-12-31 | €33.20 Million ≈ $38.81 Million |
€-13.71 Million ≈ $-16.03 Million |
-0.413x | +99.85% |
| 2014-12-31 | €12.00K ≈ $14.03K |
€-3.30 Million ≈ $-3.86 Million |
-275.250x | -11602.83% |
| 2013-12-31 | €6.16 Million ≈ $7.20 Million |
€-14.49 Million ≈ $-16.94 Million |
-2.352x | -- |
About Abionyx Pharma SA
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle that contains human recombinant apoA-I, the natural high-density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimic the structural and fu… Read more